Sanguine Announces Update on Status of Company
(firmenpresse) - ATLANTA, GA -- (Marketwire) -- 06/22/12 -- Sanguine Corp. (OTCBB: SGUI) is pleased to provide a corporate update in the form of a statement from the President of the Company, Mr. Frank Marra.
As an emerging life science technology company, we have overcome several obstacles over these past few years, all of which were exacerbated by the meltdown of the financial markets. However, in the face of these issues we have made substantial strides in furthering our research and development protocols and objectives, and now look to move forward on a number of fronts that we believe offer us the most significant opportunities for regulatory approval. To that end, we continue to be focused on the development of proprietary and novel PFC-based therapies for some of the most troubling unmet medical needs. We have incorporated both a long-term staged growth strategy along with a short term partnership and licensing model to maximize growth potential. We intend to achieve our designated objectives through two primary means: (1) the organic development, and (2) strategic alliances through carefully managed partnerships with well positioned companies, universities, research institutions and government agencies. As part of this strategy we plan on rounding out our medical advisory board by adding strategic key opinion leaders in the fields of PFC research and life science product development. Furthermore, we look to also grow the company through the acquisition of synergistic and complementary technologies that we feel add value to our product and to our shareholders.
We look forward to keeping you updated on our developments as we move forward and we encourage you to sign up for future updates from the company by calling us at our corporate offices at 678-352-9060.
For information related to the Sanguine Corp., contact Investor Relations: Lisa Kaht (678)352-9060, email: .
Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.
For information related to the Sanguine Corp., contact Investor Relations:
Lisa Kaht
(678)352-9060
email:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 22.06.2012 - 11:16 Uhr
Sprache: Deutsch
News-ID 1127014
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
ATLANTA, GA
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 171 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sanguine Announces Update on Status of Company
"
steht unter der journalistisch-redaktionellen Verantwortung von
Sanguine Corporation (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
